For: | Elloumi H, Houissa F, Hadj NB, Gargouri D, Romani M, Kharrat J, Ghorbel A. Sudden hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment. World J Gastroenterol 2007; 13(40): 5411-5412 [PMID: 17879419 DOI: 10.3748/wjg.v13.i40.5411] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v13/i40/5411.htm |
Number | Citing Articles |
1 |
Christine Little, Maura K. Cosetti. A Narrative Review of Pharmacologic Treatments for COVID‐19: Safety Considerations and Ototoxicity. The Laryngoscope 2021; 131(7): 1626 doi: 10.1002/lary.29424
|
2 |
Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 2008; 17(5) doi: 10.1002/pds.1486
|
3 |
Samir Asal, Ossama Sobhy, Omneya Ismail, Essam Bedewy. Study of the effect of combined interferon and ribavirin therapy on the hearing profile of hepatitis C virus patients. The Egyptian Journal of Otolaryngology 2015; 31(4): 237 doi: 10.4103/1012-5574.168359
|
4 |
Piotr Rzymski, Dorota Zarębska-Michaluk, Robert Flisiak. Could chronic HBV infection explain Beethoven's hearing loss? Implications for patients currently living with hepatitis B. Journal of Infection 2023; 87(3): 171 doi: 10.1016/j.jinf.2023.06.006
|
5 |
Lisa Evans DeWald, Chloe Starr, Terry Butters, Anthony Treston, Kelly L. Warfield. Iminosugars: A host-targeted approach to combat Flaviviridae infections. Antiviral Research 2020; 184: 104881 doi: 10.1016/j.antiviral.2020.104881
|
6 |
Mohammad Reza Sharifian, Shima Kamandi, Hamid Reza Sima, Mohammad Ali Zaringhalam, Mehdi Bakhshaee. INF-αand Ototoxicity. BioMed Research International 2013; 2013: 1 doi: 10.1155/2013/295327
|
7 |
Debasis Das. Viral Proteases and Their Inhibitors. 2017; : 189 doi: 10.1016/B978-0-12-809712-0.00008-3
|
8 |
Debasis Das, Jian Hong, Shu-Hui Chen, Guangyi Wang, Leonid Beigelman, Scott D. Seiwert, Brad O. Buckman. Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors. Bioorganic & Medicinal Chemistry 2011; 19(16): 4690 doi: 10.1016/j.bmc.2011.06.079
|
9 |
Vu Le, Ted Bader, Javid Fazili. A case of hearing loss associated with pegylated interferon and ribavirin treatment ameliorated by prednisone. Nature Clinical Practice Gastroenterology & Hepatology 2009; 6(1): 57 doi: 10.1038/ncpgasthep1317
|
10 |
Gulden Eser Karlidag, Turgut Karlidag, Kutbettin Demirdag, Erol Keles. The effects of pegylated interferon/lamivudine therapy on auditory functions in patients with chronic hepatitis B. Auris Nasus Larynx 2011; 38(3): 312 doi: 10.1016/j.anl.2010.10.007
|
11 |
Takuya Kitada, Takashi Narimatsu, Seiko Yamaguchi. Sudden hearing loss in a patient with chronic hepatitis C treated with pegylated interferon α2a and ribavirin. Kanzo 2009; 50(7): 371 doi: 10.2957/kanzo.50.371
|
12 |
Mizuki Tanaka, Shiori Hasegawa, Satoshi Nakao, Kazuyo Shimada, Ririka Mukai, Kiyoka Matsumoto, Mitsuhiro Nakamura, Jinn-Moon Yang. Analysis of drug-induced hearing loss by using a spontaneous reporting system database. PLOS ONE 2019; 14(10): e0217951 doi: 10.1371/journal.pone.0217951
|
13 |
Min Ki Shin, Tae Hyo Kim, Kang Ju, Chang Yoon Ha, Hyun Ju Min, Woon Tae Jung, Ok Jae Lee. A case of sudden-onset hearing loss in a patient treated with peginterferon α-2b and ribavirin for chronic hepatitis C. The Korean Journal of Hepatology 2009; 15(3): 370 doi: 10.3350/kjhep.2009.15.3.370
|